That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey.

Venture Global LNG is on track to inaugurate liquefied natural gas (LNG) production at its Plaquemines export plant in ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.

Shares of Gilead Sciences Inc. GILD were unchanged Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.54% to 6,051.25 and Dow ...

The agency identified 20 cases of serious liver damage associated with Ocaliva in the latest setback for a drug once seen as a potential blockbuster.

Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...

By sharing scientific progress and making it universally available, the world can achieve a future free from Aids. The fight ...

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...

Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.